Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course

Authors:
Jocelyn S. Chapman From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Jocelyn S. Chapman in
Current site
Google Scholar
PubMed
Close
 MD
,
Saurabh Asthana From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Saurabh Asthana in
Current site
Google Scholar
PubMed
Close
 PhD
,
Lindsay Cade From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Lindsay Cade in
Current site
Google Scholar
PubMed
Close
,
Matthew T. Chang From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Matthew T. Chang in
Current site
Google Scholar
PubMed
Close
 PharmD
,
Zhen Wang From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Zhen Wang in
Current site
Google Scholar
PubMed
Close
 MD
,
Charles J. Zaloudek From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Charles J. Zaloudek in
Current site
Google Scholar
PubMed
Close
 MD
,
Stefanie Ueda From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Stefanie Ueda in
Current site
Google Scholar
PubMed
Close
 MD
,
Eric A. Collisson From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Eric A. Collisson in
Current site
Google Scholar
PubMed
Close
 MD
, and
Barry S. Taylor From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
From the Departments of Obstetrics, Gynecology, and Reproductive Sciences, Medicine, Bioengineering and Therapeutic Sciences, Radiology and Biomedical Imaging, Pathology, Laboratory Medicine, and Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California; and (Present address) Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by Barry S. Taylor in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

Cancer is currently classified and treated using an approach based on tissue of origin. Ambiguous or incorrect diagnoses, however, are common and often go unnoticed. Clinical cancer sequencing can provide diagnostic precision, therapeutic direction, and hereditary cancer risk assessment. This report presents a patient with an initial diagnosis of metastatic pancreatic adenocarcinoma (PDA), a disease with a dismal prognosis. Tumor sequencing revealed genomic abnormalities inconsistent with PDA, instead suggesting serous ovarian cancer. This molecular rediagnosis was further refined by the identification of a BRCA2 truncating mutation in the tumor, subsequently confirmed to be a germline event. These findings prompted the initiation of platinum-based chemotherapy, which produced a life-altering response, and referral to genetic counseling for her offspring. These results suggest that clinical tumor sequencing can simultaneously clarify diagnoses, guide therapy, and inform familial risk, even in patients with end-stage metastatic disease, making the case for the development of specific strategies to deploy sequencing coupled with big data in oncology to improve clinical cancer management.

Correspondence: Eric A. Collisson, MD, Department of Medicine, Division of Hematology and Oncology, Helen Diller Family Comprehensive Cancer Center, 1450 3rd Street, San Francisco, CA 94158. E-mail: collissonlab@gmail.com; Barry S. Taylor, PhD, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065. E-mail: taylorb@mskcc.org

Supplementary Materials

    • Supplemental Material (PDF 864 KB)
  • Collapse
  • Expand